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Introduction
Xerostomia is one of the most frequent side effects that affects many head and neck cancer (HNC) patients after radiation therapy and has a major impact on quality of life (1) . Limiting the dose to the parotid glands (PGs) reduces the probability of developing xerostomia (2) (3) (4) . Although multiple studies have investigated the relation between dose and the risk of xerostomia, substantial variability in this relationship remains unexplained (2, 3) . A possible reason for this variation is that dosimetric parameters (and baseline xerostomia scores) are not the only explaining variables, but that patient-specific characteristics, such as intrinsic radiosensitivity, also affect the development of late xerostomia (5) . Unexplained variability could, moreover, result from inconsistency in the assessment of xerostomia (ie, patient-rated xerostomia, because this is a subjective measure) (6) . More specifically, the individual experience of a side effect with similar function loss varies widely among individual patients, depending on many aspects, such as interpretation of the questions and general quality of life (7) . A more quantitative measure of late xerostomia may lead to improvement of prediction models by increasing the consistency of the endpoint.
A surrogate endpoint early after treatment to evaluate late xerostomia is not only interesting to understand the development of xerostomia better, but would also be desirable and beneficial to potentially improve the time and costeffectiveness of future clinical studies in HNC patients. Additionally, this could also contribute to the physicianepatient dialogue at the end of treatment to provide patients with a more reliable prognosis regarding the expected severity of xerostomia for the next few years. Moreover, it can support selection of patients who do not recover from acute xerostomia for potential future therapeutic strategies of xerostomia, such as adult stem cellebased therapy (8, 9) .
Computed tomography (CT) image acquisition, which is routinely used for radiation therapy treatment planning and response assessment, would be an ideal modality to quantify changes of radiated tissues, because it is rapid, relatively cheap, and widely available.
To identify quantitative candidate surrogates for assessing xerostomia, PG characteristics were quantified by extracting image biomarkers (IBMs) of the PGs before and after radiation therapy and by calculating the differences (DIBMs). The main objective of this study was to test the hypothesis that DIBMsdeither combined with other predictive factors or notdwere associated with late xerostomia and to test whether an early posttreatment model based on these DIBMs could serve as a surrogate marker for late xerostomia.
Methods and Materials Patients
The 107 HNC who were prospectively included in this study were treated with radiation therapy, either in combination with concurrent chemotherapy or cetuximab or not, between June 2008 and April 2012. Patients with salivary glands tumors, those who previously (or 1 year after) underwent surgery or radiation therapy in the head and neck area were excluded from this study. Moreover, patients without follow-up data 12 months after radiation therapy were excluded. For a detailed description of the radiation protocols we refer to the article of Christianen et al (10) . Briefly, most patients were treated with intensity modulated radiation therapy that was optimized to spare the PGs without compromising the dose to the target volumes (11, 12) , using a simultaneous integrated boost technique. Generally, 70 Gy (2 Gy per fraction) was administered to the primary tumor and pathologic lymph nodes over the course of 6 or 7 weeks (6 or 5 fractions per week, respectively). The majority of patients received elective radiation to the cervical lymph node levels of 54.25 Gy (1.55 Gy per fraction) (13) . More patient characteristics are depicted in Table 1 .
For all patients a standardized planning CT scan (Somatom Sensation Open, Siemens; voxel size, 0.94 Â 0.94 Â 2.0 mm 3 ; 100-140 kV) was acquired 2 weeks before treatment. Six weeks after radiation therapy a second CT scan was acquired together with the last assessment of acute toxicity. Both scans were acquired with a thermoplastic mask in radiation therapy treatment positioning. This study was approved the medical ethics commission, and all participating patients gave informed consent.
Endpoints
Patient-rated xerostomia scores were evaluated prospectively on a routine basis, before radiation therapy, weekly during radiation therapy, and subsequently 6 weeks and 6 and 12 months after radiation therapy using the European Organization for Research and Treatment of Cancer QLQ-H&N35 questionnaire, as part of the standard follow-up program at the department of Radiation Oncology of the University Medical Center Groningen (2, 14) . The primary endpoint of this study was moderate to severe patient-rated xerostomia at 12 months after radiation therapy (Xer 12m ). This corresponds to the 2 highest scores of the 4-point Likert scale (not, a bit, quite a bit, a lot).
Quantification of PG changes in DIBMs
The PGs were delineated on the planning CT scan according to the consensus guidelines of Brouwer et al (15) . Using deformable image registration, delineations were warped to the repeat CT scan in Mirada RTx (Mirada Medical). The warped contours were manually corrected if necessary.
All image biomarkers were extracted from the planning and the repeat CT with in-house-developed software that was implemented in MATLAB (version R2014a; The MathWorks). Subtraction of the pre-from the posttreatment 
Reference model
A reference prediction model for late xerostomia based on the predictors found by Beetz et al (2) (mean dose to the contralateral PG and the baseline xerostomia) was fitted to the dataset (Fig. 1, " reference model"). The patient-reported xerostomia at start of radiation therapy (Xer baseline ) was dichotomized as none versus any. The PG that received the least amount of mean dose was considered contralateral.
DIBM selection for late xerostomia
To investigate the associations between the potential DIBMs and Xer 12m (① in Fig. 1 Stepwise forward selection, based on log-likelihood (18), was used to select the most important predictors (P<.01). The internal validity of the variable selection was estimated with a bootstrap procedure. The entire variable selection procedure (variable normalization, preselection, and forward selection) was repeated in 1000 bootstrapped samples (ie, with replacement). From the resulting models the most frequently selected variables were considered for the final models.
The selected model's optimism was estimated by calculating the difference between the performance of the models in each bootstrap and in the original sample, as suggested by the TRIPOD statement (19) .
The model's performance was quantified in terms of discrimination with the area under the receiver operating characteristic curve (AUC), the Nagelkerke R 2 , and the discrimination slope. Model calibration was tested with the Hosmer-Lemeshow test and by calculating the slope and intercept of a logistic regression model of the linear predictor derived from the predicted probability of moderate to severe late xerostomia (variable) against the actual xerostomia outcome (response). The coefficients were corrected for optimism accordingly. The R packages Regression Modeling Strategies (version 4.3-1) (20) were used for these purposes.
Relation PG dose and selected DIBMs
Linear regression was performed to investigate the relation of mean PG dose to the selected DIBMs (② in Fig. 1 ). Both PGs were considered separately in investigating this relation. Model performance was measured as the explained variance (R 2 ), and normality of the residuals of the regression models was checked. DIBMs and other predictive variables
First, the addition of mean PG dose to the model with selected DIBMs and Xer baseline was investigated. Second, the relation between DIBMs and acute xerostomia 6 weeks after radiation therapy (Xer 6w-post , moderate to severe) was investigated (③ in Fig. 1 ), to analyze whether the selected DIBMs were a direct substitute measure of acute xerostomia scores. If the assumption that acute and late xerostomia scores are related would be correct (④ in Fig. 1 ), then the selected DIBMs could actually be a measure of acute xerostomia rather than late xerostomia. Therefore, the presumed assumption was tested by investigating the logistic relation between Xer 6w-post and Xer 12m . Subsequently, a multivariable analysis and variable selection was performed to investigate whether the Xer 6w-post contained additional information to the DIBMs to predict late xerostomia (⑤ in Fig. 1 ). Baseline xerostomia was also considered for these analyses. Actual xerostomia incidences were depicted over time to 
Results

Reference model
Moderate to severe xerostomia 12 months after radiation therapy (Xer 12m ) was reported by 32 (30%) of the 107 patients. The reference model based on mean PG dose and Xer baseline was fitted to the dataset. The model characteristics and the performance measures (AUC 0.76, R 2 Z 0.28) are depicted in Table 2 (Reference model).
DIBMs selection for late xerostomia
The most frequently selected DIBM variable was DPGsurface (a visual representation is depicted in Fig. 2 van (Fig. 3A) (Fig. 3B) . The residuals of the regression models were reasonably normally distributed.
DIBMs and other predictive variables
Initial (planning) PG mean dose did not significantly add to a model with DPG-surface in terms of predicting late Xer 12m (likelihood ratio test; PZ.16). Performance measures improved slightly, but no difference was seen after internal validation (Table 2) .
A significant univariable logistic relation was found between DPG-surface and acute xerostomia scores at the same point in time, 6 weeks after radiation therapy (Xer 6w-post ) (PZ.017; OR 0.93, 95% CI 0.87-0.99; ③ in (Table 2) . Again, mean PG dose could not improve the model (likelihood ratio test; PZ.27). Calibration of all presented models was good ( Table 2 , Hosmer-Lemeshow test, calibration intercept and slope).
Depicting the actual moderate to severe xerostomia incidences, Figure 4 shows that DPG-surface was able to significantly differentiate between patients with high and low xerostomia incidence at 6 and 12 months. Using the complete early posttreatment model (DPGsurface, Xer baseline , and Xer 6w-post ) resulted in an even better distinction (Fig. 4B) : the actual reported xerostomia differences of patients with high (>50%) and low (<50%) predicted risk were substantial.
Finally, using the same classification-based early posttreatment model for patients with moderate to severe xerostomia 6 weeks after radiation therapy (Xer 6w-post Z 1) showed that the predictions of the early posttreatment model could significantly differentiate between patients who recovered and those still suffering from xerostomia at 6 and 12 months (Fig. 4C) . This suggests that DPG-surface contributes in differentiating between patients who have persistent xerostomia up to 12 months and those who recover. Two patients had no reported xerostomia scores at 6 months.
Discussion
In this study a significant relationship was shown between the geometric DIBM (DPG-surface) and late xerostomia. DPG-surface added significantly and independently to acute toxicity scores in predicting late xerostomia. Moreover, the performance of the models based on DPG-surface (with or without acute toxicities) was better than the reference model based on PG dose. Those observations together suggest that DPG-surface contains additional information on patient-specific development of late xerostomia. Mean PG dose did not add significantly to any of the DPG-surface models in this cohort. A possible explanation could be that DPG-surface and Xer 6w-post , which result from radiation dose, contain the same information as the PG mean dose; however, this should be confirmed in an external dataset.
High correlation between DPG-volume and DPGsurface was observed. Prediction of late xerostomia was good with both variables, but DPG-surface performed better than DPG-volume (Supplementary data 2; available online at www.redjournal.org). It can be hypothesized that surface change holds more information, because it also includes information on the shape of the PG. However, this observation may be limited to the current dataset; hence more research is necessary to investigate whether this can be confirmed in other datasets. Furthermore, in this study the absolute DPG-volume and DPG-surface were investigated; similar performance was achieved with proportional change.
A nonlinear (eg, quadratic) relation between mean PG dose and DPG-surface (or volume) was observed (ie, PG surface reduction increased with increasing the mean dose up to 30-40 Gy), but for PGs that received higher doses the PG surface reduction decreased again. This suggests that PGs react differently to higher doses, which might be due to direct necrosis of the PG cells inducing inflammatory swelling, instead of controlled apoptosis (21) , which than compensates (partly) for the radiation-induced volume decrease.
Although there is no study to our knowledge that has investigated DPG-surface, many studies reported reductions of PG volumes after radiation therapy (22) (23) (24) (25) (26) (27) . In line with our results, the studies with adequate patient numbers observed a significant, but weak, relationship between mean PG dose and volume decrease (rZ0.41 [24] , rZ0.26 [25] ). This means that a large amount of unexplained variation remains. A possible explanation for these findings is variation in individual radiation sensitivity of PGs, or mean PG dose may not be not the most optimal dosimetric parameter (9) . In the present study significant associations were found between: DPG-surface and late xerostomia (① in Fig. 1 ), the PG dose and DPG-surface (② in Fig. 1 ), and PG dose and late xerostomia (Fig. 1, "reference model") . This is the first study that verified all these relationships simultaneously and developed a normal tissue complication probability model to predict late xerostomia with a quantitative measure from CT imaging. Belli et al (28) showed a relation between PG shrinkage and acute xerostomia scores. Another study (25) observed in a limited cohort (n 24, >12 months' follow-up) that small mid-treatment PG volume loss was associated with a longer period of xerostomia recovery for patients receiving a relative high mean PG dose (>35.7 Gy, n 11). These counterintuitive findings might be explained by the nonlinear relation of the dose with DPG-surface shown in the present study. This relation suggests that a high PG dose may result in small DPG-surface (or volume), because this is potentially due to inflammatory PG swelling, which in turn might be related to the longer period of xerostomia recovery.
Hence, in this specific group of patients, DPG-surface alone might not optimally represent radiation therapy damage. In contrast, for patients with both a high PG dose and large PG change, DPG-surface still indicated high risk to develop late xerostomia in the present study.
Parotid gland surface reduction was related to acute xerostomia scores. However, a stronger relation was observed between PG surface reduction and late xerostomia (Xer 12m ). Moreover, not only did acute xerostomia add predictive information to DPG-surface in predicting late xerostomia, also DPG-surface added to acute xerostomia. These results suggest that DPG-surface yields unique information about the patient-specific capability of the PG to recover from radiation damage (also see Fig. 4C ) and is not only a quantitative substitute of Xer 6w-post .
The model with DPG-surface, baseline, and acute xerostomia scores (6 weeks after treatment) predicts late xerostomia with an exceptionally good performance, reflected in the good discrimination measures (AUC 0.90, 95% CI 0.84-0.96; and AUC bootstrapped 0.86). Early prediction of late xerostomia could improve effectiveness of future clinical studies, because the 1-year compliance is approximately 60% (1-year overall survival of HNC approximately 70% [29] together with other dropout factors). First, an early surrogate could increase the follow-up information and thereby the time and costeffectiveness of clinical studies. Second, adequate Abbreviations: b Z regression coefficients; DPG-surface Z parotid gland surface difference after À before radiation therapy; AUC Z area under the receiver operating characteristic curve; DS Z discrimination slope; HL Z Hosmer-Lemeshow test; OR Z odds ratio; PG Z parotid gland; R 2 Z Nagelkerke R 2 ; Xer baseline and Xer 6w-post Z xerostomia score at baseline and 6 weeks after radiation therapy. Apparent Z evaluated using the full dataset the same data. Corrected for optimism with bootstrapping the entire variable selection procedure. * No variable selection was performed for internal validation of the reference model.
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International Journal of Radiation Oncology Biology Physics prediction of late xerostomia can contribute to the physician-patient dialog, in order to discuss the chance of xerostomia recovery. Third, selection of patients who do not recover from acute xerostomia (Fig. 4C) can be beneficial for potential future treatments for xerostomia, such as stem cell therapy (9) .
The relationship of DPG-surface with dose suggests that DPG-surface is a biomarker that measures physiologic response. However, a correlation like this does not necessarily make this biomarker a surrogate for a clinical marker (30) . A candidate surrogate marker should also have a relationship with the clinical endpoint, which is patient-rated late xerostomia in this study. This study shows a significant association between DPG-surface and Xer 12m . In addition, the model of DPG-surface together with acute xerostomia (Xer 6w-post ) also meets the criteria mentioned above. Therefore, this model can be considered as a candidate surrogate marker for late xerostomia. Subsequently, external validation or a clinical trial is needed to verify whether the model of DPG-surface together with Xer 6w-post can be used as a validated surrogate marker (31, 30).
Unfortunately no contrast was used for the CT scan 6 weeks after treatment. Although this does not influence the geometric DIBMs, it could explain why no strong relation was observed between late xerostomia and CT intensityebased DIBMs, such as mean intensity/density change that has been reported in other studies (28) . Univariable analysis, however, did show a significant relation between mean CT intensity and Xer 12m (PZ.019). Textural IBM changes (refer to Supplementary material 4 [available online at www.redjournal.org] for textural IBM details) were also tested in the present cohort, as described in a previous study (5) . Univariable analysis showed that some textural IBMs were significantly associated with Xer 12m ; however, none gave a significant addition to DPG-surface.
Textural IBM changes may yield similar information as DPG-surface or be biased owing to the presence of metal artefacts in some patients. These IBMs were not extensively discussed in this study, because they gave no conclusive rejectable results, owing to the above discussed limitations.
Furthermore, because the final models presented in our report may be susceptible to limitations of the chosen variable selection procedure, LASSO regularization, which is an alternative variable selection approach, was additionally performed and resulted in very comparable variable selection frequencies (DPG-surface was the most selected DIBM: 49% of the bootstrapped samples). This suggests a relatively large robustness of the associations found in this dataset, independent of the method of analysis. Additionally, modalities that provide functional information, such as positron emission tomography and magnetic resonance imaging, could contribute in determining functionality loss of the PG gland and could further improve quantifying and understanding the development of xerostomia.
Conclusion
Parotid gland surface reduction between start and 6 weeks after radiation therapy (DPG-surface) was significantly associated with the development of xerostomia 6 to 12 months after completing radiation therapy. 
